tetano
Editor, Senior Moderator
NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019.
[h=1]OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.[/h] Del Campo J[SUP]1[/SUP], Pizzorno A[SUP]#[/SUP][SUP]2[/SUP], Djebali S[SUP]#[/SUP][SUP]3[/SUP], Bouley J[SUP]1[/SUP], Haller M[SUP]1[/SUP], P?rez-Vargas J[SUP]1,[/SUP][SUP]4[/SUP], Lina B[SUP]2,[/SUP][SUP]5[/SUP], Boivin G[SUP]6[/SUP], Hamelin ME[SUP]6[/SUP], Nicolas F[SUP]1[/SUP], Le Vert A[SUP]1[/SUP], Leverrier Y[SUP]3[/SUP], Rosa-Calatrava M[SUP]2[/SUP], Marvel J[SUP]3[/SUP], Hill F[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an oligomerized NP, which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against viral challenge with three different influenza A subtypes, isolated several decades apart and induced a reduction in viral load. When co-administered with IIV, OVX836 was even more effective in reducing lung viral load.
PMID: 30701093 PMCID: PMC6344521 DOI: 10.1038/s41541-019-0098-4
[h=1]OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.[/h] Del Campo J[SUP]1[/SUP], Pizzorno A[SUP]#[/SUP][SUP]2[/SUP], Djebali S[SUP]#[/SUP][SUP]3[/SUP], Bouley J[SUP]1[/SUP], Haller M[SUP]1[/SUP], P?rez-Vargas J[SUP]1,[/SUP][SUP]4[/SUP], Lina B[SUP]2,[/SUP][SUP]5[/SUP], Boivin G[SUP]6[/SUP], Hamelin ME[SUP]6[/SUP], Nicolas F[SUP]1[/SUP], Le Vert A[SUP]1[/SUP], Leverrier Y[SUP]3[/SUP], Rosa-Calatrava M[SUP]2[/SUP], Marvel J[SUP]3[/SUP], Hill F[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an oligomerized NP, which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against viral challenge with three different influenza A subtypes, isolated several decades apart and induced a reduction in viral load. When co-administered with IIV, OVX836 was even more effective in reducing lung viral load.
PMID: 30701093 PMCID: PMC6344521 DOI: 10.1038/s41541-019-0098-4